2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12D.07 Efficacy and Safety of Savolitinib for MET-Altered Non-Small Cell Lung Cancer (NSCLC) In First-Line Setting: A Case Series

EP.12D.07 Efficacy and Safety of Savolitinib for MET-Altered Non-Small Cell Lung Cancer (NSCLC) In First-Line Setting: A Case Series

Back to course

Pdf Summary

This case series examines the efficacy and safety of savolitinib as a first-line treatment for MET-altered non-small cell lung cancer (NSCLC), specifically focusing on patients with EGFR wild-type (EGFRw) variations. Conducted by a team at Beijing TianTan Hospital, Capital Medical University, the study included four patients with MET-altered NSCLC, out of which three had MET amplification and one had a MET exon14 skipping mutation.<br /><br />The study involved male patients aged between 64 and 85, all diagnosed with adenocarcinoma. Three of the patients also suffered from brain metastases. The objective was to observe the primary tumor's response to savolitinib, analyze its progression-free survival (PFS), and evaluate intracranial progression in cases with brain metastases.<br /><br />Results showed that three patients achieved partial responses with savolitinib, demonstrating primary tumor shrinkage with durable responses, irrespective of brain metastatic status. Specific PFS durations were 17.4, 30.1, and 19.1 months for cases 1, 2, and 4, respectively. Brain metastases in cases 2 and 4 responded well to a combination of savolitinib and stereotactic radiotherapy, exhibiting notable intracranial PFS.<br /><br />Regarding safety, patients experienced manageable side effects; three reported peripheral edema leading to a dosage reduction, but no severe adverse events were recorded. The study highlighted the potential of savolitinib in shrinking tumors and maintaining response in MET-altered NSCLC, including cases with brain metastasis.<br /><br />The study concluded that savolitinib, particularly when complemented by local radiotherapy, offers an effective first-line treatment modality for MET-altered NSCLC. It underscored the need for further investigations into the resistance mechanisms against MET TKI, specifically focusing on brain metastases. The research was supported by the Beijing Natural Science Foundation.

Asset Subtitle

Xiaoyan Li

Meta Tag

Speaker Xiaoyan Li

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

savolitinib

MET-altered NSCLC

EGFR wild-type

brain metastases

adenocarcinoma

progression-free survival

stereotactic radiotherapy

peripheral edema

tumor shrinkage

Beijing TianTan Hospital